Skip to main content
PRISM BioLab Co.,LTD logo

PRISM BioLab Co.,LTD — Investor Relations & Filings

Ticker · 206A ISIN · JP3833190006 T Manufacturing
Open in API
Filings indexed 17 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country JP Japan
Listing T 206A

About PRISM BioLab Co.,LTD

https://prismbiolab.com/ja/

PRISM BioLab is a biotechnology company specializing in drug discovery and development. It utilizes its proprietary PepMetics® technology platform to create orally available, small molecule drugs that target protein-protein interactions (PPIs), which are often considered 'undruggable'. The platform designs molecules that mimic key peptide structures, such as α-helices and β-turns, to modulate these interactions. The company's primary mission is to develop novel therapeutics for intractable diseases that currently lack effective treatments. PRISM BioLab advances its pipeline through both internal research programs and strategic collaborations with pharmaceutical partners.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 89% confidence The document is a confirmation letter (“確認書”) under the Financial Instruments and Exchange Act, submitted to the Kanto Finance Bureau, certifying the appropriateness of the half-year report’s disclosures. It does not contain any financial data itself nor the actual interim report, but is an officer attestation. Under the CERTIFICATION RULE, such a document should be classified as a general regulatory filing (RNS), not as the interim report (IR).
2026-05-14 Japanese
半期報告書－第15期(2025/10/01－2026/09/30)
Interim / Quarterly Report Classification · 93% confidence The document is titled “半期報告書” (semi‐annual report) submitted under the Financial Instruments and Exchange Act for the period October 1, 2025 to March 31, 2026. It includes detailed financial statements (sales, losses, cash flows), management discussion, business overview, risk factors, corporate information, shareholding schedules, etc. It is a comprehensive interim financial report (half‐year), not merely an announcement. Therefore, it matches the definition of an Interim / Quarterly Report (Code: IR). H1 2026
2026-05-14 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It serves as a formal certification by the CEO regarding the accuracy of the company's Annual Securities Report (Yukashoken Hokokusho). Since it is a regulatory filing required by law to accompany financial reporting but does not constitute the financial report itself, and given the specific nature of this certification, it falls under the general regulatory filing category.
2025-12-24 Japanese
有価証券報告書－第14期(2024/10/01－2025/09/30)
Annual Report Classification · 100% confidence The document is a formal '有価証券報告書' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It covers a specific fiscal year (第14期, 2024-10-01 to 2025-09-30) and includes detailed financial statements, management analysis, and corporate information. This corresponds to the Japanese equivalent of a 10-K filing. FY 2025
2025-12-24 Japanese
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) in the header and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related regulations concerning a change in a major shareholder. Section 2 details the change, showing the shareholder's voting rights percentage before and after the event, and the date of the change (July 9, 2025). This structure and content strongly indicate a regulatory filing related to a significant change in shareholding, which aligns best with the 'Major Shareholding Notification' (MRQ) definition, as it reports changes in significant share ownership levels crossing thresholds. Although it is a Japanese regulatory filing, MRQ is the closest fit among the provided codes for a major shareholder change report.
2025-07-17 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the Representative Director of PRISM BioLab, confirming the accuracy of the contents of the semi-annual report. Per the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 14
2025-05-14 Japanese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.